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DM1 Myotonic dystrophy type 1 
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MBLN-1 Muscleblind like splicing regulator 1 
NMSC Non-melanoma skin cancers 
SCC Squamous cell carcinoma 
SD Standard deviation 
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Novelty and Impact: 
Patients with myotonic dystrophy type 1 (DM1), an inherited tri-nucleotide repeat disorder, are 
at high risk of certain cancers. However, risk of skin cancers in those patients was not 
comprehensively evaluated. Using data from the UK Clinical Practice Datalink, we showed that 
DM1 patients are at high risk of basal cell carcinoma (HR=5.8, p<0.0001), and possibly 
melanoma (HR=2.4, p=0.24). The findings provide evidence that skin cancer is part of the DM 
phenotype.  
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Disclaimer: The results were presented at the 2017 International Conference on 
Pharmacoepidemiology & Therapeutic Risk Management. 
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ABSTRACT 
Myotonic dystrophy type 1 (DM1) is an inherited multisystem neuromuscular disorder caused by  
a CTG trinucleotide repeat expansion in the DMPK gene. Recent evidence documents that DM1 
patients have an increased risk of certain cancers, but whether skin cancer risks are elevated is 
unclear. Using the U.K. Clinical Practice Research Datalink (CPRD), we identified 1,061 DM1 
patients and 15,119 DM1-free individuals matched on gender, birth year (±2 years), attending 
practice, and registration year (±1 year). We calculated the hazard ratios (HRs) and 95% 
confidence intervals (CIs) for the association of DM1 diagnosis with skin cancer risk using Cox 
proportional hazards models, for all skin cancers combined and by histological subtype. Follow-
up started at the latest of the age at practice registration, DM1 diagnosis/control selection or 
January 1st 1988, and ended at the earliest of the age at first skin cancer diagnosis, death, transfer 
out of the practice, last date of data collection or the end of the CPRD record (October 31, 2016). 
During a median follow-up of 3.6 years, 35 DM1 patients and 108 matched DM1-free 
individuals developed a skin cancer. DM1 patients had an increased risk of skin cancer overall 
(HR=5.44, 95% CI=3.33-8.89, p<.0001), and basal cell carcinoma (BCC) (HR=5.78, 95% 
CI=3.36-9.92, p<.0001). Risks did not differ by gender, or age at DM1 diagnosis (P-
heterogeneity>0.5). Our data confirm suggested associations between DM1 and skin neoplasms 
with the highest risk seen for BCC. Patients are advised to minimize ultraviolet light exposure 
and seek medical advice for suspicious lesions.  
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INTRODUCTION 
Myotonic dystrophy type 1 (dystrophia myotonica, DM1, also called Steinert's disease) is an 
autosomal dominant multisystem disorder caused by unstable (CTG)n trinucleotide repeat 
expansion in the 3’ noncoding region of the dystrophia myotonica protein kinase (DMPK) gene 
on chromosome 19q13.31-3. The prevalence of DM1 ranges from 0.5/100,000 in Taiwan4 to 
1/550 in Northestern Quebec5; the estimate for Europe ranges from 6.8/100,000 to 36.2/100,0006-
8. Myotonia and muscle weakness are the main clinical presentations of DM1. Other prevalent 
manifestations include posterior subcapsular cataracts, cardiac conduction abnormalities, central 
nervous system dysfunctions, and endocrine abnormalities9. Recently, large epidemiological 
studies indicated that cancer is part of the DM phenotype10-12, but lacked the information 
required to adequately assess the risk of skin cancers.  
Case reports and small case series have suggested a possible link between DM and both 
pilomatricoma -a rare, benign, calcifying cutaneous tumor arising from the hair matrix,13 and 
basal cell carcinoma (BCC)13-15. Large DM registry studies from the U.S., Italy, and the U.K.  
have shown that cancers of the skin are the most common cancer in DM1 patients (n=32/781, 
6/255, and 4/231, respectively)16-18; however, comparisons of risk with that in the general 
population were not available. Two small studies from Italy comparing dermatological findings 
of DM1 patients with controls showed significantly higher frequencies of pilomatricoma19, 
dysplastic nevi19, 20, and melanoma19 in DM1 patients, but found contradictory results with 
BCC19, 20. Similar results for pilomatricoma were reported in a single Spanish center study using 
patient medical records21.  No significant BCC prevalence difference between DM1 patients and 
controls was noted; however, DM1 patients developed BCC at a younger age than controls.  
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In the current study, we used computerized primary care physician records from the U.K. to 
evaluate the risk of skin cancers (overall and by subtype) in a large cohort of patients with DM1 
compared with age and sex-matched DM1-free controls.  
METHODS 
Data sources  
The U.K. Clinical Practice Research Datalink (CPRD) is one of the world’s largest anonymized 
longitudinal databases of electronic primary care medical records, derived from more than 4 
million active patients and 650 general care practices around the U.K.22 CPRD started in June 
1987, first known as Value Added Medical Products (VAMP) Research Databank, but earlier 
data are available. The database includes demographic information, clinical diagnoses, test 
results, immunization and referral records, selected lifestyle factors, and prescription records. 
Clinical diagnoses are recorded using Read codes, a unique clinical terms coding system used in 
the U.K. National Health Service (https://data.gov.uk/dataset/uk-read-code). All patients in 
CPRD are linkable to practice level Indices of Multiple Deprivation (IMD, a proxy measure for 
socioeconomic measure), and approximately 57% of the participating CPRD practices in the 
U.K. and 75% of CPRD practices located in England are linkable to the Hospital Episode 
Statistics (HES) inpatient records database from April 1997 to February 201623.  
Patients attending CPRD participating practices were found to be representative of the U.K. 
population with regard to age and sex22.  
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Study population 
From the October 2016 CPRD data release, we identified all patients with a DM1 diagnosis 
(n=1,061) using Read codes F392011: Steinert’s disease, and F392000: Dystrophia myotonica 
(Steinert's disease). For each DM1 patient, we randomly selected up to 20 individuals from the 
pool of DM1-free individuals registered in the same practice and who were alive at the index 
date (defined as the date at 1st DM1 record for patients diagnosed after their date of practice 
registration, or the date of practice registration, if diagnosed prior to enrollment). DM1 patients 
and DM1-free individuals were additionally matched on gender, year of birth (± 2 years), and 
practice registration year (± 1 year); the total number of DM1-free individuals was 15,119. 
Figure 1 provides a flow chart of participant selection.  
The study protocol was reviewed and approved by the CPRD Independent Scientific Advisory 
Committee (ISAC; protocol 16_005RA2R). Our use of CPRD database was approved by the 
National Institutes of Health Office of Human Subject Research Protection.  
Skin cancer outcomes 
The outcome of interest was the first skin cancer (all types combined and stratified by 
histological subtypes) occurring during follow-up. In the main analysis, we used Read codes 
(available in Supplemental Table 1) to identify skin cancers from primary care physicians’ 
records. Primary care physicians in the UK are the center of health care delivery; they treat, refer, 
and follow-up, therefore their records capture patient information through the health care 
continuum. In a sensitivity analysis, we used ICD-10 codes C43 (malignant melanoma of skin), 
and C44 (other malignant neoplasms of skin) to identify skin cancers from hospital records using 
HES database. This analysis included the subset of patients who are linkable to HES.  
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Statistical analysis 
We used Cox proportional hazard regression models to calculate hazard ratios (HRs) and 95% 
confidence intervals (CIs) for the association of having DM1 with the first diagnosis of skin 
cancer occurring during follow-up, overall and by subtype. Skin cancer risk in DM1 patients was  
compared with that in matched DM1-free subjects. The proportional hazards assumption was 
evaluated using Schoenfeld residuals, and no significant violation was observed.  
We used age as the time scale for all analyses. Follow-up started at the latest of age at index date, 
or January 1st 1988 (after the start of CPRD database). For the sensitivity analysis using the HES 
database, we started follow-up at the latest of age at index date or April 1st 1997 (after the start of 
HES data linkage). Late entry into the cohort was accounted for in PROC PHREG procedure, 
SAS 9.324. Follow-up ended at the earliest of age at 1st record of any skin cancer, death, transfer 
out of the practice, last data collection, or end of database record (for CPRD: October 31, 2016, 
for HES: February 29, 2016). For subtype analysis, skin cancer diagnosis other than the subtype 
of interest were treated as censored (i.e. follow-up ended at 1st skin cancer of any type). 
The matched design of DM1 and DM1-free subjects was accommodated by stratifying the 
baseline hazard function on the matching ID. The models were additionally adjusted for yearly 
average number of clinic visits, calculated as the total number of clinical events (maximum one 
per day) after start of follow-up until 1 year prior to the skin cancer or censor date, divided by the 
number of years of follow-up.  
The analysis was further stratified by gender (male, female), patient registration year at the clinic 
(<1991, 1991-2000, >2000), age at DM1 diagnosis (<30, ≥30), and geographical region of the 
practice (north, central, south). We tested the difference of the magnitude of the associations 
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between DM1 and skin cancer across categories using a Wald test, computed as the difference of 
the estimates squared divided by the sum of the variances, as the estimates for different strata are 
independent. 
To assess the robustness of our findings, we conducted several sensitivity analyses. First, we 
repeated the analysis restricted to DM1 patients (and their matched controls) who had their 1st 
DM1 event recorded at the current clinic after the start of CPRD (on or after January 1st 1988; 
N=538 and 6,849 for DM1 patients and DM1-free subjects, respectively). This would restrict the 
analysis to patients with prospectively recorded diagnoses and thus bring greater certainty about 
the exact date of first diagnosis of DM1 and skin cancer.  Second, we repeated the analysis 
including only patients with first DM1 record after the date CPRD identified the practice 
recording to be “up-to-standard”22 (N=403 and 4,849 for DM1 patients and DM1-free subjects, 
respectively). Again, this would ensure better data quality. Third, we excluded individuals with 
skin cancer records before the start of study follow-up (N=21 DM1, and 73 DM1-free). Fourth, 
we restricted the analysis to a subset of patients who were linked to the HES database (N=573 
and 7,614 for DM1 patients and DM1-free subjects with unique HES ID, respectively), in which 
skin cancer outcomes were identified only from the hospital records. Lastly, we restricted the 
analysis to DM1 patients with unique HES ID who had DM diagnosis records in both HES (ICD-
10 code G71.1) and CPRD (N=374) and their 5,435 DM1-free matched subjects. 
All p values were two-sided with statistical significance defined as p<0.05. All analyses were 
conducted using SAS version 9.3 (SAS Institute, Cary, NC) and R version 3.3.3. 
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RESULTS 
Characteristics of DM1 patients and matched DM1-free subjects 
DM1 patients were first diagnosed between 1944 and 2016, at a mean age of 32.7 years 
(SD=18.6). The mean age at the start of follow-up was 38.1 years (SD=17.0) for DM1 patients 
and 35.6 years (SD=16.6) for the matched DM1-free subjects. The median follow-up time was 
5.4 years for DM1 patients and 3.5 years for the DM1-free individuals. Approximately 51% of 
both cohorts were female, and 80% were from England. More clinic visits were noted for the 
DM1 patients than the DM1-free cohort (mean number of annual visits=10.4 (SD=12.2) and 5.0 
(SD=8.4), respectively). The characteristics of DM1 patients and matched DM1-free subjects are 
presented in Table 1. 
The association between DM1 and skin cancer risk 
During 90,455 person-years of follow-up, 35 DM1 and 108 matched DM1-free subjects 
developed skin cancer, corresponding to crude incidence rates of 434.6 and 131.1 per 100,000 
person-years among DM1 and DM1-free subjects, respectively. The mean (SD) age at 1st skin 
cancer diagnosis during follow-up in DM1 patients was 57.3 years (11.0), versus 63.3 years 
(13.0)  in the DM1-free subjects. 
In multivariable analysis, DM1 patients had a statistically significantly increased risk of all skin 
cancers combined compared with their matched DM1-free subjects (HR=5.44, 95% CI=3.33- 
8.89, p<0.0001). The risk was highest for BCC (HR=5.78, 95% CI=3.36-9.92, p<0.0001). 
Although not statistically significant, DM1 patients had an approximately two-fold increase in 
melanoma risk (HR=2.40, 95% CI=0.56-10.31, p=0.24). No squamous cell carcinomas (SCCs) 
were reported in DM1 patients. Similar results were observed when excluding patients with skin 
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cancer diagnoses within the first 6 months of the start of follow-up (potential prevalent cancer 
cases)(Table 2).   
In stratified analyses, there was no evidence of differences in the magnitude of risk of overall 
skin cancer or BCC by gender (p-heterogeneity=0.99 and 0.56, respectively) or geographical 
region (p-heterogeneity=0.98 and 0.88, respectively). We also found no evidence of 
heterogeneity in the risk of all skin cancer combined and BCC by registration year to the practice 
(p-heterogeneity=0.91 and 0.72, respectively), or age at DM1 diagnosis (p-heterogeneity=0.40 
and 0.50, respectively) (Table 3).  
Results from sensitivity analyses were consistent with those of the main analysis. Specifically, 
similar results were observed from models restricted to: 1) patients diagnosed with DM1 after the 
start of CPRD (HR=5.61, 95% CI=3.01-10.45 for all skin cancers combined, and HR=6.19, 95% 
CI=3.18-12.08 for BCC), 2) patients diagnosed with DM1 after the clinic “up-to-standard” date 
(HR=5.08, 95% CI=2.45-10.53 for skin cancer combined, and HR=5.84, 95% CI=2.71-12.57 for 
BCC only). In analysis restricted to patients with no prior history of skin cancer, the observed 
risk estimates slightly attenuated for both all skin cancer combined (HR=4.87, 95% CI=2.85-
8.29), and for BCC (HR=4.86, 95% CI=2.68-8.82). 
In subgroup analysis using HES database (573 DM1 and 7,614 DM1-free), having DM1 was 
associated with an approximately four-fold excess in the risk of non-melanoma skin cancers 
(NMSC) (HR=3.78, 95% CI=1.44-9.90, p=0.01). These data also suggested a possible risk for 
melanoma skin cancer, however not statistically significant (HR=3.38, 95% CI=0.25-46.17, 
p=0.36). 
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When restricting the analysis to patients with DM codes in both HES and CPRD (N=374) and 
their matched DM1-free cohort (N=5,435), DM1 patients showed an approximately seven-fold 
excess in the risk of all skin cancer combined (HR=7.41, 95% CI=3.31-16.59) and that of BCC 
(HR=6.71, 95% CI=2.86-15.76). The risk estimates were attenuated when the analyses were 
repeated in DM1 cases whose diagnosis were identified from one source (CPRD only) (for all 
skin cancer combined: HR=4.54, 95% CI=2.33-8.85, for BCC: HR=5.34, 95% CI=2.51-11.39).  
DISCUSSION 
In this large cohort of 1,061 patients with DM1 and 15,119 DM1-free matched individuals, we 
used electronic primary care health records to quanify the risk of skin cancer in those patients. 
We showed that DM1 patients are at a particularly high risk for basal cell carcinoma, and 
possibly melanoma, but no evidence of an excess risk of squamous cell carcinoma.   
DM1 patients in this study had a 6-fold increase in the risk of BCC compared with matched 
DM1-free individuals. On the contrary, none of the DM1 patients had records of squamous cell 
carcinoma compared with 6 cases in the DM1-free individuals, suggesting that DM1 patients 
may be at a lower risk of cutaneous SCC. Because NMSC, particularly BCC is generally 
underreported in cancer registries25, 26, adequate comparative studies were not available with the 
exception of data from Denmark which suggested an excess risk of NMSC in DM patients 
(standardized incidence ratio (SIR)=2.08; 95% CI=1.2-3.4)10. Results related to risk of SCC need 
to be interpreted with caution since a validation study of primary care recording for cutaneous 
SCC in the UK has shown that physicians tend to use non-organ specific codes for recording 
cutaneous SCC (53%)27. Here, we used skin-specific SCC codes to ensure organ specificity, 
therefore it is possible that SCC cases were underascertained. Yet, concerns related to possible 
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differential misclassification bias are lessened since both DM1 patients and DM1-free subjects 
were selected from the same practice and therefore similar reporting patterns are expected. Our 
estimated risk for melanoma in this study agrees with that previously reported in other DM 
population- and clinic-based studies (SIR=2.3 in Scandinavian patients10, 1.7 in patients from the 
Basque, Spain12, and 2.05 in a US cohort11); none of these risk estimates reached statistical 
significance. 
The molecular mechanism underlying skin tumorigenesis in DM1 patients is still unknown, but 
several mechanisms have been hypothesized, including aberrant ß-catenin accumulation via the 
Wnt/ß-catenin signaling pathway13, and depletion/ malfunction of the RNA binding protein- 
muscleblind like splicing regulator 1(MBLN-1)14. A recent study suggested a role for Vitamin D 
homeostasis in DM skin abnormalities including dysplastic nevi; an inverse correlation between 
Vitamin D level and the presence of dysplastic nevi was observed20.  
Our study showed no gender differences in the relative risks of BCC (HR=5.09 vs 7.01, in men 
and women), or melanoma (3.27 vs 1.97, in men and women) in DM1 patients. This finding is 
similar to those previously reported in DM1 patients from Sweden and Denmark for cancers 
other than that of the reproductive organs10. Yet, this contrasts skin cancer statistics from the U.K. 
general population, in which men are at higher risk of BCC28, and women are at higher risk of 
melanoma29. Other known skin cancer risk factors include older age, fair skin color, light eye 
color and a tendency to burn on sun exposure30-33. In our study, DM1 patients appeared to 
develop melanoma skin cancer at a relatively early age. All melanoma cases among DM1 
patients were diagnosed at <65 years of age (median age=43.8 years) versus 70% in the controls. 
In the U.K., about 50% of melanoma cases are diagnosed among people aged ≥65 years34.  The 
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age difference at skin cancer diagnosis was less clear in BCC, in which DM1 patients were 
diagnosed at a slightly younger age than DM1-free controls (58.5 vs. 62.3) . It is possible that the 
early age at skin cancer diagnosis in DM1 patients represents ascertainment bias due to the 
frequent and close medical surveillance they experience in the course of their care for a serious, 
multisystem disorder.  
Our data showed no significant association between age at DM1 diagnosis (an indicator of 
disease severity) and skin cancer risk. This is similar to our previous finding in DM-related brain 
cancer, in which no association between risk and age at DM diagnosis was observed35. Similarily, 
tumor development in DM patients did not correlate with the size of nucleotide repeat measured 
in patient blood (another proxy of disease severity) in several studies12, 16, 17, 19.  
The strengths of the current study include its relatively large sample size, longitudinal design that 
ensured the identification of incident cancer cases, and the use of matched comparison cohort 
design.  The ascertainment of cancer diagnosis from clinical records minimized the possible 
recall bias often associated with survey studies. The use of data from the primary health care 
setting allowed the inclusion of the full spectrum of DM1 cases, minimizing selection bias 
associated with identifying patients only from hospital records or tertiary care centers. 
Additionally, and in contrast to most cancer registries, the CPRD data captured NMSC.  
Several limitations existed including our inability to directly adjust for the known skin cancer 
risk factors such as sun exposure and cutaneous phenotype, which are not uniformly captured 
with UK primary care records. Suggestive associations between risk of skin malignancies and 
pigmentation phenotype or reaction to sun exposure have been observed in a previous DM 
study36.  Given the close medical attention DM1 patients recieve, it is likely that our observed 
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association is affected by detection bias. To minimize this possibility, we adjusted our models for 
the yearly average number of doctor visits. Additionally, it is possible that DM1 diagnosis in 
CPRD may not be accurately recorded. We investigated DM1 diagnosis validity in 516 DM1 
patients with any HES record, and found that 374 of them had DM1 records in both sources. The 
stronger associations we observed when restricting the analysis to those with DM1 diagnosis in 
both sources suggest that our results are valid and that possible bias that may be associated with 
DM1 misclassification is pulling the results toward the null.  
In conclusion, our study showed that patients with DM1 are at increased risk of basal cell 
carcinoma and possibly melanoma.  It is important that DM1 patients adhere to sun protective 
behaviors, minimizing exposure to ultraviolet light, and to seek medical advice if suspicious skin 
lesions appeared.  Molecular studies aiming at elucidating the biological pathways involved in 
DM1 skin carcinogenesis are warranted, since it may provide novel insights into our 
understanding of DM-related carcinogenesis, in general. 
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TABLES  
Table 1. Study cohort characteristics 
 
 DM1 patients 
(N=1,061) 
DM1-free subjects 
(N=15,119) 
Characteristics N (%) N (%) 
Follow-up (person-years) 8054.3 82400.4 
Age at start of follow-up, year   
   ≤20 155 (14.6%) 2446 (16.2%) 
   >20, ≤30 207 (19.5%) 3609 (23.9%) 
   >30, ≤40 210 (19.8%) 3068 (20.3%) 
   >40, ≤50 206 (19.4%) 2729 (18.0%) 
   >50 283 (26.7%) 3267 (21.6%) 
Age at 1st DM diagnosis in CPRD, year  
    ≤15 191 (18.0%)  
    >15, ≤30 286 (27.0%)  
    >30, ≤45 285 (26.9%)  
    >45, ≤60 225 (21.2%)  
    >60 74 (7.0%)  
Gender   
    Male 520 (49.0%) 7350 (48.6%) 
    Female 541 (51.0%) 7769 (51.4%) 
Year at registration to the practice   
    Before 1991 336 (31.7%) 4239 (28.0%) 
    1991-2000 293 (27.6%) 4689 (31.0%) 
    After 2000 432 (40.7%) 6191 (40.9%) 
Practice located in England 844 (79.5%) 12346 (81.7%) 
UK Region of included practices1   
    North 370 (34.9%) 5079 (33.6%) 
    Central 340 (32.0%) 4701 (31.1%) 
    South 351 (33.1%) 5339 (35.3%) 
Socioeconomic status2 based on practice location, 
quintile   
     1 (Most affluent) 158 (14.9%) 2206 (14.6%) 
     2 181 (17.1%) 2467 (16.3%) 
     3 196 (18.5%) 2795 (18.5%) 
     4 221 (20.8%) 3175 (21.0%) 
     5  305 (28.7%) 4476 (29.6%) 
Average Annual number of practice visit3   
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    0-1 187 (17.6%) 6049 (40.0%) 
    >1, ≤5 224 (21.1%) 4295 (28.4%) 
    >5 650 (61.3%) 4775 (31.6%) 
1 North: North West England, Yorkshire & The Humbler, Northern Ireland, North East England, and Scotland 
Central: East of England, Wales, West Midlands, and East Midlands 
South: South West England, South East Coast, South Central England and London 
2 Using practice level Indices of Multiple Deprivation data 
3 Average number of clinic visit/year after the start date until 1 year prior to the end of follow-up 
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Table 2. Risk of skin cancers, overall and by histological subtype in patients with DM1.  
 
 All Patients (N=16,180)  
Excluding individuals with skin cancer event 
occurred 
within 6 months of start of follow-up 
(N=16,171) 
Outcome N event (crude incident rate1)  HR2 (95% CI) P  
N event 
(crude incident rate1)   HR2 (95% CI) p 
1st skin cancer3          
     DM1-free subjects4 108 (131.07) 1.00 (reference)   100(121.36) 1.00 (reference)  
     DM1 patients  35 (434.55) 5.44 (3.33-8.89) <.0001  34 (422.14) 5.81 (3.52-9.59) <.0001 
         
Melanoma          
     DM1-free subjects 20 (24.27) 1.00 (reference)   20 (24.27) 1.00 (reference)  
     DM1 patients  <5 (37.25) 2.40 (0.56-10.31) 0.24  <5 (37.25) 2.40 (0.56-10.31) 0.24 
          
Basal cell carcinoma          
     DM1-free subjects 80 (97.09) 1.00 (reference)   73 (88.59) 1.00 (reference)  
     DM1 patients  30 (372.47) 5.78 (3.36-9.92) <.0001  29 (360.06) 6.48 (3.71-11.34) <.0001 
1 per 100,000 person-years. 
2 Models were stratified on matched set, and adjusted for average number of clinic visit/year after the start date until 1 year prior to the end of follow-up.  
3 In addition to the melanoma and BCC cases in the table, there were 6 SCC (all in DM1-free subjects), and <5 skin cancer, not otherwise specified in all patients; person-year 
of follow-up=82400 for DM1-free subjects, and 8054 for DM1 patients in analysis of all patients, and 82399 and 8054, respectively in analysis excluding cases within first 6 
months of follow-up 
4 DM1-free individuals were matched to DM1 patients on gender, birth year (±2 years), attending practice, and registration year (±1 year). 
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Table 3. The association between skin cancer and DM1 stratified by selected characteristics. 
 
 1st skin cancer (all subtypes)1  Basal cell carcinoma 
Characteristics DM1 patients 
DM1-free 
subjects2 HR3 (95% CI) P 
 DM1 patients 
DM1-free 
subjects2 HR3 (95% CI) p 
 N event  (crude incident rate4)  
N event  
(crude incident rate4) 
Gender          
      Male 18 (451.96) 63 (151.81) 5.54 (2.86-10.73) <.0001  15 (376.63) 46 (110.84) 5.09 (2.45-10.54) <.0001 
      Female 17 (417.53) 45 (110.02) 5.51 (2.64-11.49) <.0001  15 (368.41) 34 (83.13) 7.01 (3.10-15.90) <.0001 
        Pheterogeneity   0.99     0.56  
Registration year          
     Before 1991 18 (471.86) 55 (145.05) 5.06 (2.63-9.74) <.0001  16 (419.43) 41 (108.13) 5.94 (2.93-12.05) <.0001 
     1991-2000 9 (374.18) 29 (103.08) 6.39 (2.21-18.54) <.001  8 (332.61) 21 (74.64) 7.43 (2.19-25.27) <.01 
     After 2000 8 (436.12) 24 (146.80) 4.68 (1.58-13.87) 0.01  6 (327.09) 18 (110.10) 3.75 (1.12-12.57) 0.03 
        Pheterogeneity   0.91     0.72  
Age at 1st DM diagnosis         
     < 30 5 (122.06) 12 (29.95) 3.02 (0.68-13.39) 0.15  <5 (97.64) 8 (19.97) 3.22 (0.51-20.46) 0.22 
     ≥ 30 30 (758.00) 96 (226.77) 5.94 (3.53-9.98) <.0001  26 (656.94) 72 (170.08) 6.25 (3.55-11.01) <.0001 
        Pheterogeneity   0.40     0.50  
Region5          
     North 12 (398.23) 43 (145.66) 5.18 (2.21-12.12) <.001  11 (365.04) 35 (118.56) 6.65 (2.68-16.55) <.0001 
     Central 11 (434.89) 32 (132.46) 5.49 (2.36-12.75) <.0001  8 (316.28) 22 (91.07) 4.77 (1.80-12.63) <.01 
     South 12 (477.80) 33 (114.89) 5.81 (2.39-14.11) <.001  11 (437.98) 23 (80.08) 5.98 (2.33-15.40) <.001 
        Pheterogeneity   0.98     0.88  
1 Includes melanoma, basal cell carcinoma, squamous cell carcinoma of skin and other skin cancer, not otherwise specified.  
2 DM1 patients and DM1-free subjects were matched on gender, birth year (±2 years), attending practice, and registration year (±1 year). 
3 Models were stratified on matched set, and adjusted for average number of clinic visit/year after the start date to 1 year prior to the end of follow-up.  
4 per 100,000 person-years. 
5 North: North West England, Yorkshire & The Humbler, Northern Ireland, North East England, and Scotland 
Central: East of England, Wales, West Midlands, and East Midlands  
   South: South West England, South East Coast, South Central England and London 
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